|
Kangji Medical Holdings Limited (9997.hk) Valation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Kangji Medical Holdings Limited (9997.HK) Bundle
Découvrez le véritable potentiel de Kangji Medical Holdings Limited (9997HK) avec notre calculatrice DCF de qualité professionnelle! Ajustez les hypothèses clés, explorez divers scénarios et évaluez comment les changements affectent l'évaluation de Kangji Medical - le tout dans un seul modèle Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 544.5 | 734.8 | 837.1 | 985.7 | 1,073.6 | 1,192.8 | 1,325.2 | 1,472.3 | 1,635.7 | 1,817.3 |
| Revenue Growth, % | 0.00 | 34.95 | 13.92 | 17.76 | 8.92 | 11.10 | 11.10 | 11.10 | 11.10 | 11.10 |
| EBITDA | 339.7 | 454.8 | 624.5 | 494.5 | 598.9 | 727.2 | 808.0 | 897.7 | 997.3 | 1,108.0 |
| EBITDA, % | 62.39 | 61.90 | 74.60 | 50.17 | 55.78 | 60.97 | 60.97 | 60.97 | 60.97 | 60.97 |
| Depreciation | 8.7 | 12.6 | 23.0 | 23.5 | 23.7 | 25.4 | 28.2 | 31.4 | 34.8 | 38.7 |
| Depreciation, % | 1.60 | 1.72 | 2.75 | 2.39 | 2.21 | 2.13 | 2.13 | 2.13 | 2.13 | 2.13 |
| EBIT | 331.0 | 442.2 | 601.4 | 471.0 | 575.2 | 701.8 | 779.7 | 866.3 | 962.5 | 1,069.3 |
| EBIT, % | 60.79 | 60.18 | 71.85 | 47.78 | 53.57 | 58.84 | 58.84 | 58.84 | 58.84 | 58.84 |
| Total Cash | 2,959.7 | 3,208.8 | 3,011.9 | 2,861.3 | 1,322.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 93.0 | 86.3 | 173.7 | 240.1 | 289.5 | 240.7 | 267.4 | 297.1 | 330.1 | 366.7 |
| Account Receivables, % | 17.09 | 11.75 | 20.75 | 24.36 | 26.96 | 20.18 | 20.18 | 20.18 | 20.18 | 20.18 |
| Inventories | 54.8 | 72.8 | 112.2 | 112.0 | 115.2 | 132.3 | 147.0 | 163.3 | 181.4 | 201.5 |
| Inventories, % | 10.06 | 9.91 | 13.40 | 11.36 | 10.73 | 11.09 | 11.09 | 11.09 | 11.09 | 11.09 |
| Accounts Payable | 12.1 | 19.4 | 22.1 | 36.3 | 43.8 | 36.5 | 40.6 | 45.1 | 50.1 | 55.6 |
| Accounts Payable, % | 2.23 | 2.65 | 2.64 | 3.69 | 4.08 | 3.06 | 3.06 | 3.06 | 3.06 | 3.06 |
| Capital Expenditure | -19.0 | -32.9 | -80.6 | -93.6 | -58.9 | -77.6 | -86.3 | -95.8 | -106.5 | -118.3 |
| Capital Expenditure, % | -3.49 | -4.47 | -9.63 | -9.49 | -5.48 | -6.51 | -6.51 | -6.51 | -6.51 | -6.51 |
| Tax Rate, % | 19.27 | 14.54 | 14.98 | 14.39 | 15.11 | 15.66 | 15.66 | 15.66 | 15.66 | 15.66 |
| EBITAT | 267.2 | 377.9 | 511.3 | 403.2 | 488.3 | 591.9 | 657.6 | 730.6 | 811.7 | 901.8 |
| Depreciation | 8.7 | 12.6 | 23.0 | 23.5 | 23.7 | 25.4 | 28.2 | 31.4 | 34.8 | 38.7 |
| Changes in Account Receivables | 48.8 | -26.7 | -29.7 | -33.0 | -36.6 | |||||
| Changes in Inventories | -17.1 | -14.7 | -16.3 | -18.1 | -20.1 | |||||
| Changes in Accounts Payable | -7.3 | 4.1 | 4.5 | 5.0 | 5.5 | |||||
| Capital Expenditure | -19.0 | -32.9 | -80.6 | -93.6 | -58.9 | -77.6 | -86.3 | -95.8 | -106.5 | -118.3 |
| UFCF | 121.3 | 353.6 | 329.7 | 281.2 | 408.0 | 564.1 | 562.3 | 624.6 | 694.0 | 771.0 |
| WACC, % | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 |
| PV UFCF | 536.3 | 508.2 | 536.8 | 567.0 | 598.9 | |||||
| SUM PV UFCF | 2,747.3 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 798.0 | |||||||||
| Terminal Value | 47,499.1 | |||||||||
| Present Terminal Value | 36,899.4 | |||||||||
| Enterprise Value | 39,646.7 | |||||||||
| Net Debt | -1,196.0 | |||||||||
| Equity Value | 40,842.7 | |||||||||
| Diluted Shares Outstanding, MM | 1,176.0 | |||||||||
| Equity Value Per Share | 34.73 |
What You Will Receive
- Genuine Kangji Data: Comprehensive financials – covering everything from revenue to EBIT – sourced from actual and projected figures.
- Complete Customization: Modify all essential parameters (highlighted cells) such as WACC, growth percentage, and tax rates.
- Real-Time Valuation Adjustments: Automatic recalculations to evaluate the effects of changes on Kangji's fair value.
- Flexible Excel Template: Designed for quick modifications, scenario evaluations, and in-depth forecasting.
- Efficiency and Accuracy: Eliminate the need to construct models from the ground up while ensuring precision and adaptability.
Key Features
- 🔍 Real-Life KANGJI Financials: Pre-filled historical and projected data for Kangji Medical Holdings Limited (9997HK).
- ✏️ Fully Customizable Inputs: Modify essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas evaluate Kangji's intrinsic value via the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Kangji's valuation in real-time after adjustments are made.
- Scenario Analysis: Assess and contrast outcomes based on different financial assumptions side-by-side.
How It Functions
- Step 1: Download the Excel file.
- Step 2: Examine the pre-filled Kangji Medical data (historical and projected).
- Step 3: Modify key assumptions (yellow cells) according to your analysis.
- Step 4: Observe automatic recalculations for Kangji Medical's intrinsic value.
- Step 5: Utilize the results for investment decisions or reporting.
Why Opt for This Calculator?
- Precision: Utilizes real financial data from Kangji Medical Holdings Limited (9997HK) for reliable calculations.
- Versatility: Built to allow users to freely experiment and adjust inputs as needed.
- Efficiency: Avoid the complexities of creating a DCF model from the ground up.
- Expert-Level: Crafted with the accuracy and functionality expected by CFOs.
- Intuitive: Simple to navigate, making it accessible even for those lacking advanced financial modeling skills.
Who Can Benefit from This Product?
- Individual Investors: Make well-informed decisions regarding the purchase or sale of Kangji Medical Holdings Limited (9997HK) shares.
- Financial Analysts: Enhance valuation processes with readily available financial models tailored for Kangji Medical Holdings Limited (9997HK).
- Consultants: Provide clients with prompt and precise valuation insights related to Kangji Medical Holdings Limited (9997HK).
- Business Owners: Gain insights into the valuation methods of major companies like Kangji Medical Holdings Limited (9997HK) to inform your own business strategy.
- Finance Students: Master valuation techniques through the analysis of real-world data and scenarios involving Kangji Medical Holdings Limited (9997HK).
Contents of the Template
- Pre-Filled Data: Features Kangji Medical Holdings Limited's historical financial performance and forecasts.
- Discounted Cash Flow Model: An editable DCF valuation model with automatic calculation capabilities.
- Weighted Average Cost of Capital (WACC): A dedicated worksheet for calculating WACC based on personalized inputs.
- Key Financial Ratios: Evaluate Kangji Medical's profitability, operational efficiency, and leverage metrics.
- Customizable Inputs: Easily adjust revenue growth rates, profit margins, and tax percentages.
- Intuitive Dashboard: Visuals and tables that summarize essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.